Unknown

Dataset Information

0

Weekly paclitaxel/carboplatin/trastuzumab therapy improves pathologic complete remission in aggressive HER2-positive breast cancers, especially in luminal-B subtype, compared with a once-every-3-weeks schedule.


ABSTRACT: The efficacy and tolerability of two different schedules of paclitaxel, carboplatin, and trastuzumab (PCarH) for HER2-positive, locally aggressive (stage IIB-IIIC) breast cancers were evaluated in this phase II trial.Patients were randomly assigned to receive either weekly (12 doses over 16 weeks) or once-every-3-weeks (4 doses over 12 weeks) treatment. The primary endpoint was pathologic complete remission (pCR) in the breast and axilla. To detect an assumed 35% pCR absolute difference between the two schedules, a minimum of 26 assessable patients in each group was required (two-sided ? = 0.05, ? = 0.2).A total of 56 patients were enrolled (weekly group, n = 29; every-3-weeks group, n = 27). In the intent-to-treat analysis, pCR in the breast/axilla were found in 31 patients (55%; 95% confidence interval [CI]: 41%-69%). Compared with the every-3-weeks schedule, the weekly administration achieved higher pCR (41% vs. 69%; p = .03). After adjustment for clinical and pathological factors, the weekly administration was more effective than the every-3-weeks schedule, with hazard ratio of 0.3 (95% CI: 0.1-0.9; p = .03). Interestingly, weekly administration resulted in high pCR rates in both luminal-B (HER2-positive) and ERBB2+ tumors (67% vs. 71%; p = .78), whereas luminal-B (HER2-positive) tumors benefited less from the every-3-weeks schedule compared with the ERBB2+ tumors (21% vs. 62%, p = .03). These results remain after multivariate adjustment, showing weekly administration was more effective in the luminal-B (HER2-positive) subgroup (p = .02) but not in the ERBB2+ subgroup (p = .50).A more frequent administration might improve the possibility of eradicating invasive cancer in the breast and axilla, especially in the luminal-B (HER2-positive) subtype. Further studies to validate our findings are warranted.

SUBMITTER: Yu KD 

PROVIDER: S-EPMC3662841 | biostudies-literature | 2013

REPOSITORIES: biostudies-literature

altmetric image

Publications

Weekly paclitaxel/carboplatin/trastuzumab therapy improves pathologic complete remission in aggressive HER2-positive breast cancers, especially in luminal-B subtype, compared with a once-every-3-weeks schedule.

Yu Ke-Da KD   Liu Guang-Yu GY   Chen Can-Ming CM   Li Jian-Wei JW   Wu Jiong J   Lu Jin-Song JS   Shen Zhen-Zhou ZZ   Shao Zhi-Ming ZM  

The oncologist 20130501 5


<h4>Background</h4>The efficacy and tolerability of two different schedules of paclitaxel, carboplatin, and trastuzumab (PCarH) for HER2-positive, locally aggressive (stage IIB-IIIC) breast cancers were evaluated in this phase II trial.<h4>Methods</h4>Patients were randomly assigned to receive either weekly (12 doses over 16 weeks) or once-every-3-weeks (4 doses over 12 weeks) treatment. The primary endpoint was pathologic complete remission (pCR) in the breast and axilla. To detect an assumed 3  ...[more]

Similar Datasets

| S-EPMC2216039 | biostudies-literature
| S-EPMC2875434 | biostudies-literature
| S-EPMC6368417 | biostudies-literature
| S-EPMC3500143 | biostudies-literature
| S-EPMC5697639 | biostudies-literature
| S-EPMC6861407 | biostudies-literature
| S-EPMC9588896 | biostudies-literature
| S-EPMC4362893 | biostudies-literature
| S-EPMC5955142 | biostudies-other
| S-EPMC3308312 | biostudies-literature